Compare TotalEnergies SE (TTE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs Travere Therapeutics Inc. Common Stock — how do they compare? TotalEnergies SE trades at $89.28 (market cap $196.57B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: TotalEnergies SE is far larger — about 40.3× Travere Therapeutics Inc. Common Stock's market cap, and TotalEnergies SE pays a 4.76% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TotalEnergies SE for 91 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TTE | TVTX | |
|---|---|---|
Market Cap | $196.57B | $4.88B |
Volume | 2,606,285 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $93.60 | $67.52 |
52-Week Low | $60.44 | $26.79 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $227.56B | $5.01B |
Dividend Yield | 4.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $89.64, up 1.44% today, with a bullish technical outlook and strong analyst support. The stock shows robust fundamentals with a P/E of 11.13 and net income margin of 9.08%, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent news highlights a $10B investment in Argentina and a $2.5B Q4 share buyback increase, reinforcing growth commitments. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending.
The outlook for TTE is positive, driven by strategic investments and shareholder returns, but faces risks from volatile energy prices and execution challenges. Wall Street consensus is bullish with a $95.33 price target, though investors should monitor oil price fluctuations and geopolitical factors that could impact profitability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
